DPP4 and diabetes mellitus: This suggests that DPP-4 inhibitors, which are commonly used for treating type 2 diabetes mellitus (T2DM), may offer therapeutic benefits beyond glycemic control, potentially mitigating bone resorption and reducing fracture risk [23].